MWMollie E. Wood

Mollie E. Wood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mollie E. Wood has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Labor Epidural Analgesia and Autism Spectrum Disorder in Offspring: A Population‐Based Case–Control Study

    by Taniqua T. Ingol, Jessie K. Edwards, Mollie E. Wood, Chantel L. Martin, Gabriel S. Dichter, Keith Feldman, Alan C. Kinlaw, Julie L. Daniels

    While the immediate benefits of labor epidural analgesia (LEA) are well established, recent studies have raised concerns about possible associations with autism spectrum disorder (ASD). Therefore, we examined the association between LEA and ASD in offspring. We analyzed data from mother–child dyads enrolled in the Study to Explore Early Development (2007–2020), a US multisite case–control study. Receipt of LEA during childbirth and other covariate information was ascertained from a combination of maternal self‐report, medical record abstraction, and the birth certificate. ASD classification was determined by trained psychologists using the Autism Diagnostic Observation Schedule and Autism Diagnostic Interview‐Revised. We used logistic regression to estimate the odds ratio (OR) for the association between LEA and ASD in offspring. Models were adjusted for demographic and pregnancy factors. Sensitivity analyses restricted to term deliveries, singleton pregnancies, and vaginal births were conducted. Our sample included 2039 ASD cases and 3171 controls. The prevalence of LEA use was similar among cases and controls (66% and 67%, respectively). The crude OR for the association between LEA and ASD was 0.97 (95% CI: 0.85, 1.10), and the adjusted OR was 1.02 (95% CI: 0.89, 1.17). Findings from sensitivity analyses were generally consistent with the primary results. Subtle associations emerged when the analysis was restricted to vaginal deliveries; however, they attenuated after additional adjustment for fetal distress, induced or augmented labor, and prolonged labor. Our findings do not support an association between LEA and ASD in offspring.


  • Effects of hospital and obstetric unit closures on postpartum acute care across county racial composition in rural North Carolina

    by Mekhala V. Dissanayake, John W. Jackson, Rachel Peragallo Urrutia, Chantel L. Martin, Michele Jonsson Funk, Mollie E. Wood

    Purpose: Hospital and obstetric unit closures are concentrated in the rural Southern United States, often where marginalized racial/ethnic groups reside and access to maternal health care is already strained. Given structural racism's role as a fundamental cause of inequities, we hypothesized that closure effects may vary by race and racial composition of county. Methods: We used linked North Carolina birth certificates and Medicaid claims from births occurring to rural residents from 2014 to 2019. Using a Trial Emulation Policy Approach with a Difference‐in‐Difference analysis, we estimated the effects of hospital and obstetric closures on postpartum acute care (maternal emergency department visit or hospital admission) by race and county racial composition. We categorized rural counties as lower (LNHW, <80% White) or higher (HNHW, ≥80% White) Non‐Hispanic White. Findings: We found declines in postpartum acute care associated with closures: 3.6 percentage points in LNHW counties and 1.8 percentage points in HNHW counties. We also found that marginalized groups experienced the largest declines, for example, Black versus White birthing people in LNHW counties (−7.1 vs −2.5 percentage points). Conclusions: As hospitals and obstetric units continue to close, increasing support in the postpartum period will be crucial for maternal health.


  • Severe Maternal Morbidity and Long-Term Kidney Outcomes among Pregnant Women Receiving Maintenance Dialysis

    by Lauren M. Kucirka, Kim A. Boggess, Mollie E. Wood, Johanna Quist-Nelson, Vimal K. Derebail, Jennifer E. Flythe, Andrea Chalem, Tracy A. Manuck, Michelle L. Meyer, Alison M. Stuebe, et al.

    Key Points: In the United States, one in three pregnant women receiving maintenance dialysis experienced severe maternal morbidity from 2000 to 2020. History of severe maternal morbidity was associated with higher mortality and a longer time to kidney transplantation in the years following delivery. Background: Pregnant women receiving maintenance dialysis are at high risk for adverse pregnancy outcomes. Little is known about their rates of severe maternal morbidity and the association of severe maternal morbidity with future kidney transplant wait times and mortality. Methods: This is a cohort study of women who gave birth while receiving maintenance dialysis from January 1, 2000, to December 31, 2019, as captured in the United States Renal Data System. Nonkidney severe maternal morbidity, defined by the US Centers for Disease Control and Prevention, was assessed from 4 weeks before birth to 6 weeks postpartum. Multivariable regression models examined risk factors independently associated with severe maternal morbidity. Multivariable Cox proportional hazards were stratified by the presence or absence of severe maternal morbidity to examine time to mortality, and, separately, the receipt of a kidney transplant. Results: We identified 1082 births among 986 women who were receiving dialysis at the time of birth. In total, 332 women (34%) and 342 births (32%) experienced at least one nonkidney severe maternal morbidity. The most common severe maternal morbidity events were blood transfusion (16% of all births), pulmonary edema/acute heart failure (10%), sepsis (6%), and acute respiratory distress syndrome (5%). In multivariable analyses, risk factors independently associated with severe maternal morbidity included Black or other/unknown race, body mass index >35 kg/m 2 , and dialysis initiation within 1 year before giving birth. Patients who experienced severe maternal morbidity had a higher risk of mortality than those who did not (adjusted hazard ratio, 1.69; 95% confidence interval, 1.30 to 2.19) and were less likely to receive a kidney transplant than those who did not (adjusted subhazard ratio, 0.76; 95% confidence interval, 0.59 to 0.97). Conclusions: In the United States, one in three pregnant women receiving maintenance dialysis experienced severe maternal morbidity with risk factors that included recent dialysis initiation. In the following years, the history of severe maternal morbidity was associated with higher mortality and a longer time to kidney transplantation.


  • Fertility Treatment, Female‐Factor Infertility, and Autism Spectrum Disorder: Study to Explore Early Development

    by Michelle Delahanty, Julie Daniels, Stephanie Engel, Tanya Garcia, Mollie Wood, Dani Fallin, Christine Ladd‐Acosta, Anne Steiner

    Background: Prior research on fertility treatments and autism spectrum disorder (ASD) suggests minimal association but confounding by indication limits inference. To make clinically relevant conclusions, studies should include populations who receive treatment specifically for female‐factor infertility. Objectives: We investigated the association between ovulation‐inducing medications and assisted reproductive technology (ART) and ASD. We conducted analyses in a subsample reporting female‐factor infertility to reduce confounding by indication. Methods: We used data from the Study to Explore Early Development (SEED), a 2007–2020 U.S. population‐based case–control study. Children 2.5–5 years old with and without ASD were classified using in‐person assessments. We identified fertility treatment via interview and included ovulation‐inducing medications, ART, and a combination of both. The subsample included those who were told it would be difficult to conceive and/or who attempted to conceive for > 12 months. We estimated odds ratios and 95% confidence intervals for the whole sample and the subsample using logistic regression models adjusted for age, education, parity, pre‐pregnancy body mass index, pregnancy history, smoking status, pre‐existing hypertension, and other hormonal fertility treatments. Results: There were 5210 participants in the whole sample and 1091 in the subsample. There was no association between ovulation‐inducing medications and ASD in the full sample (adjusted odds ratio [aOR] 1.04, 95% confidence interval [CI] 0.77, 1.39) and the subsample (aOR 0.87, 95% CI 0.61, 1.2). There was an increased likelihood of ASD for ART and a combination of treatments in the whole sample (ART: aOR 1.33, 95% CI 0.70, 2.52; combination: aOR 1.39, 95% CI 0.95, 2.03) compared to the subsample (ART: aOR 1.16, 95% CI 0.57, 2.36; combination: aOR 1.08, 95% CI 0.69, 1.68). Conclusions: In our data, fertility treatment was not associated with ASD. Additional research should restrict analyses to populations with similar indications to untangle whether observed associations are due to treatment or factors related to uptake.

  • Pregnancy identification method as a source of bias in studies of prenatal exposures using real-world data

    by Chase D Latour, Jessie K Edwards, Michele Jonsson Funk, Elizabeth A Suarez, Kim Boggess, Mollie E Wood

    Researchers typically identify pregnancies in healthcare data based on observed outcomes. This approach misses pregnancies that received prenatal care but whose outcomes were not recorded, potentially inducing selection bias in prenatal effect estimates. Alternatively, prenatal encounters can be used to identify pregnancies with unobserved outcomes, but this requires addressing loss to follow-up (LTFU). We simulated 10 000 000 pregnancies and estimated the total effect of treatment on preeclampsia. Across 36 scenarios, we varied the treatment effect on miscarriage and/or preeclampsia; percent LTFU (5% or 20%); and cause of LTFU: (1) measured covariates, (2) unobserved miscarriage, and (3) both. We created analytic samples to address LTFU—observed deliveries, observed deliveries and miscarriages, and all pregnancies—and estimated treatment effects using nonparametric direct standardization. Risk differences (RDs) and risk ratios (RRs) from the samples were similarly biased when LTFU was due to miscarriage (log-transformed RR bias: −0.12 to 0.33 among observed deliveries, −0.11 to 0.32 among observed deliveries and miscarriages, and −0.11 to 0.32 among all pregnancies). When predictors of LTFU were measured, only estimates among all pregnancies were unbiased (−0.27 to 0.33, −0.29 to 0.03, and −0.02 to 0.01, respectively). While including all pregnancies does not prevent bias, it quantifies the extent of selection, enabling direct assessment of its potential impact on findings.


  • Impact of Increasing Midwifery‐Led Prenatal Care on Birth Outcomes: An Application of the g‐Formula and Target Trial Emulation

    by Elizabeth Simmons, Anna Austin, Mollie Wood, Alyssa J. Mansfield, Karen Sheffield‐Abdullah, Kavita Singh

    Background: Compared to undergoing prenatal care with a physician, care with a midwife reduces the risk of medical interventions and complications during labor and delivery among low‐risk pregnant individuals. However, many analyses that assess the relationship between midwifery‐led care and birth outcomes condition on live births, potentially inducing a type of collider bias. Objective: The objective was to analyse the change in prevalence of caesarean deliveries, primary and secondary postpartum haemorrhage, obstetric trauma, and maternal infection under hypothetical scenarios where midwifery‐led prenatal care was increased. Methods: Our sample included commercially insured, midwifery‐eligible pregnant people in an insurance claims data source. We used g‐computation to assess the change in prevalence of caesarean deliveries, primary and secondary postpartum haemorrhage, obstetric trauma, and maternal infection if 10%, 20%, and 50% more pregnant people enrolled in prenatal care with a midwife rather than a physician, among a cohort of low‐risk pregnant people with commercial insurance in the U.S. between 2004 and 2015. Results: With a 50% increase in midwifery‐led care compared with no increase, we found the prevalence of caesarean deliveries was reduced by 5.4 percentage points (95% confidence interval [CI] −5.7, −5.1) and of maternal infection decreased by 1.3 percentage points (95% CI −1.6, −1.0), while the prevalence of primary postpartum haemorrhage increased by 0.5 percentage points (95% CI 0.4, 0.6) and of secondary postpartum haemorrhage increased by 0.6 percentage points (95% CI 0.4, 0.7). Conclusions: Increasing midwifery‐led prenatal care reduced the prevalence of caesarean deliveries and maternal infections and slightly increased the prevalence of primary and secondary postpartum haemorrhage. Our results were similar to those of studies among live birth cohorts.


  • Periconceptional Hormonal Contraception Use and Autism Spectrum Disorder in the Study to Explore Early Development

    by Michelle T. Delahanty, Stephanie Engel, Dani Fallin, Tanya Garcia, Christine Ladd‐Acosta, Anne Steiner, Mollie Wood, Julie L. Daniels

    Background: Prior studies report associations between periconceptional exposure to natural and synthetic oestrogen and progesterone and autism spectrum disorder (ASD). Hormonal contraception contains synthetic forms of one or both hormones. Although hormonal contraception is highly effective when consistently used, unintended pregnancy can occur with irregular use. Given the popularity of hormonal contraception, foetal exposure in utero is possible, yet the potential consequences are unknown. Objectives: We investigated the association between periconceptional hormonal contraception use and the development of ASD in offspring. Methods: We analysed data from the Study to Explore Early Development (SEED), a population‐based case–control study conducted in select US states, from 2007 to 2020. Children with and without ASD were identified from clinical/education sources and vital records, respectively, and enrolled at ages 2.5–5 years. We confirmed the ASD case status by in‐person developmental assessment. We assessed hormonal contraception via a structured interview. We assessed the associations between ASD and hormonal contraception exposure separately for contraception discontinued in the 3 months prior to pregnancy and contraception continued during pregnancy using logistic models to estimate odds ratios (OR) adjusted for biological mother age, education, parity, pre‐pregnancy body mass index (BMI), and presence of gynaecologic conditions and 95% confidence intervals (CI). Results: Of 5210 participants, 9.9% reported discontinuing hormonal contraception use before pregnancy and 2.3% reported continuing use during pregnancy. A suggestive association was found between ASD and hormonal contraception use during pregnancy (aOR 1.38,95% CI 0.93, 2.05). There was no association with use prior to pregnancy (aOR 1.02, 95% CI 0.84, 1.25). Conclusions: Discontinuation of hormonal contraception prior to conception was not associated with ASD. The prevalence of hormonal contraception use during pregnancy was low. Results were imprecise and may be impacted by recall bias and unmeasured confounding by indication and health behaviours related to planning pregnancy.


  • Open Access

    Comparative effectiveness of initiating nifedipine versus labetalol in early gestation for chronic hypertension in pregnancy

    by Chase Doyne Latour, Madison Ponder, Kim A. Boggess, Jessie K. Edwards, Michele Jonsson Funk, Sharon Peacock Hinton, Mireille E Schnitzer, Elizabeth A Suarez, Mollie E Wood

    Background Limited data exist on the comparative effectiveness and safety of first-line medications to treat chronic hypertension in pregnancy. We compared nifedipine versus labetalol initiation before 23 weeks’ gestation for risk of pregnancy loss (miscarriage or stillbirth) and preterm birth (Methods We identified pregnancies in Merative’s MarketScan commercial claims data with estimated last menstrual periods between July 1, 2016 and February 1, 2022. We included those with a new nifedipine or labetalol fill before 23 weeks’ gestation. We estimated risks, risk differences (RDs) per 100 pregnancies, and risk ratios (RRs) among nifedipine versus labetalol initiators using a weighted Aalen-Johansen estimator to account for confounding and informative censoring. We also conducted a post hoc analysis to estimate the comparative effect of nifedipine versus labetalol on risk of preeclampsia. Results We identified 987 nifedipine and 4,570 labetalol initiators during the study period. The weighted risk of pregnancy loss was 7.0% among nifedipine and 6.0% among labetalol initiators (RD=1.1 [-0.7, 2.8]; RR=1.18 [0.87, 1.59]). Weighted risks of preterm birth were 29.4% versus 22.2%, respectively (RD=7.2 [3.9, 10.5], RR=1.32 [1.13, 1.55]). In post hoc analyses, the weighted risks of preeclampsia were 38.6% versus 33.9%, respectively (RD=4.7 [0.7, 8.7], RR=1.14 [1.01, 1.28]). Findings were consistent across various sensitivity analyses. Conclusions Compared to labetalol initiators, nifedipine initiators experienced an increased risk of preterm birth but not pregnancy loss. The elevated risk of preterm birth may be explained by an increased risk of preeclampsia among nifedipine initiators, resulting in medically indicated preterm birth. What is new? Initiating nifedipine, compared to labetalol, before 23 weeks’ gestation as a first-line antihypertensive was associated with a 7.2 percentage point increased risk of preterm live birth (95% CI: 3.9, 10.5) and 4.7 percentage point increased risk of preeclampsia (95% CI: 0.7, 8.7). Nifedipine and labetalol were associated with a similar risk of pregnancy loss (risk difference: 1.1 per 100 pregnancies [95% CI: -0.7, 2.8]). These findings were robust across multiple sensitivity analyses. What are the clinical implications? Initiating labetalol, compared to nifedipine, prior to 23 weeks’ gestation for treatment of chronic hypertension in pregnancy may lead to lower risk of preeclampsia and preterm live birth in real-world settings. While high-quality data from clinical trials clearly support antihypertensive therapy for chronic hypertension in pregnancy, our findings illustrate that the first-line medications may have different comparative safety and effectiveness profiles. These data are important for informing shared decision-making between providers and patients managing chronic hypertension in pregnancy.


  • Association between maternal periconceptional dietary patterns and occurrence of orofacial clefts

    by Erin G Sley, Tania A Desrosiers, Daniela Sotres-Alvarez, Suzan L Carmichael, Joanna Maselko, Mollie E Wood, Elizabeth C Ailes, Wendy N Nembhard, Wei Yang, Andrew F Olshan, et al.

    Orofacial clefts (OFC) are a common birth defect with few known risk factors (eg, smoking). Maternal diet is associated with birth defects, though the relationship with OFC is less clear as studies typically only investigate single nutrients. We assessed the association between periconceptional maternal diet and OFC in the United States, using the National Birth Defects Prevention Study (1997-2011), including 3649 cases (2480 cleft lip with/without palate [CL/P] and 1169 cleft palate [CP]) and 10 584 controls (infants without a birth defect). Using latent class analysis, we derived dietary patterns based on relative consumption of self-reported food items via food frequency data. We used logistic regression to estimate adjusted odds ratios (aORs) and 95% CIs for the effect of dietary patterns on OFC. Four patterns were identified: Prudent (reference), Western, Low-Calorie Western, and Mexican. The Western diet had increased odds of CL/P (aOR: 1.3 [95% CI, 1.2-1.5]) and CP (aOR: 1.2 [95% CI, 1.1-1.4]). Low-Calorie Western (CL/P aOR: 1.2 [95% CI, 1.0-1.4]; CP aOR: 1.0 [95% CI, 0.9-1.2]) and Mexican diets (CL/P aOR: 1.1 [95% CI, 0.9-1.3]; CP aOR: 0.8 [95% CI, 0.6-1.1]) had a weaker or null association. Findings underscore the importance of further investigation into the effect of periconceptional diet on OFC occurrence.

  • Challenges in estimating effects of hypothetical interventions on resources patterned by structural racism: an example in a rural North Carolina Medicaid population

    by Mekhala V Dissanayake, John W Jackson, Chantel L Martin, Rachel Peragallo Urrutia, Michele Jonsson Funk, Mollie E Wood

    Structural racism has likely shaped the geographic distribution and resource allocation of rural populations and marginalized racial/ethnic groups. We sought to (1) quantify disparities in severe maternal morbidity (SMM) and distributions of resources by race and racial composition of county, and (2) determine whether a hypothetical intervention on resources would reduce racial disparities in SMM, using linked birth certificates and claims from Medicaid beneficiaries giving birth from 2014 to 2019 in rural North Carolina (61 rural counties, 77 665 births). We used ratio of mediator probability weights to enact a hypothetical intervention that would equalize distributions of pregnancy care provider ratios and obstetric units across race and racial composition of county. Despite observed disparities in the distributions of resources and SMM, we were unable to demonstrate that the hypothetical interventions would reduce SMM. This may be due to a lack of common support—marginalized groups never experienced the more optimal extremes of the healthcare resources distributions that privileged groups did. Our findings may have implications for the use of causal inference methods for addressing health disparities more broadly: if distributions of resources among privileged groups are outside those that marginalized groups experience, hypothetical interventions on these distributions cannot be emulated with data.